Medicine and Dentistry
Ovarian Cancer
100%
Bevacizumab
100%
Vasculotropin
100%
Vasculotropin A
100%
Vasculotropin C
100%
Vasculotropin D
100%
Metastatic Carcinoma
50%
Vasculotropin B
50%
Antiangiogenic Therapy
33%
Malignant Neoplasm
16%
Primary Tumor
16%
Drug Efficacy
16%
Angiogenesis Inhibitor
16%
Survival Analysis
16%
Tissue Microarray
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Bevacizumab
100%
Vasculotropin
100%
Vasculotropin C
100%
Vasculotropin A
100%
Vasculotropin D
100%
Vasculotropin B
50%
Antiangiogenic Therapy
33%
Malignant Neoplasm
16%
Primary Tumor
16%
Angiogenesis Inhibitor
16%
Immunology and Microbiology
Vasculotropin
100%
Vasculotropin A
100%
Vasculotropin C
100%
Bevacizumab
100%
Vasculotropin D
100%
Vasculotropin B
50%
Angiogenesis Inhibitor
16%
Drug Efficacy
16%
Biochemistry, Genetics and Molecular Biology
Vascular Endothelial Growth Factor
100%
Bevacizumab
100%
Vascular Endothelial Growth Factor A
54%
Vascular Endothelial Growth Factor C
54%
Factor D
54%
Vascular Endothelial Growth Factor B
27%
Tissue Microarray
9%
Drug Efficacy
9%
Keyphrases
Bevacizumab Resistance
100%
Combinatorial Analysis
9%